1 Introduction

Type 2 Diabetes Mellitus (DM) is a metabolic disorder caused by pancreatic deficiency in insulin secretion or defects in its function, or both [1, 2], principally resulting from being overweight and lacking physical activity. In the past two decades, DM has drawn much attention in the research literature and is recognized as a major threat to global development [3, 4]. It is the most common metabolic disorder and the most common cause of death in eastern populations [5]. Two decades ago, its prevalence had already increased to the level of epidemic illness [6, 7], decreasing longevity by five to 10 years [8]. With an estimated 1.6 million deaths directly caused by diabetes in 2016, WHO estimates that diabetes was the seventh leading cause of death in 2016.

A considerable number of people with diabetes experience emotional difficulties which have been associated with treatment complications, including depressed mood, reduced quality of life, poor self-care behavior, negative appraisals of insulin therapy, reduced glycemic control and subsequent adverse cardiovascular outcomes, including mortality [9, 10]. There is evidence of a bidirectional association between depressive symptoms and DM, where depressive symptoms are associated with an increased risk of developing DM over time and DM levels are associated with an increased risk of developing depression over time [11,12,13]. In Iran, the prevalence of depressive symptoms among patients with diabetes is between 71 and 78 percent [14, 15], compared to between 28 and 34 percent in the general population [16].

A recent study suggests that insulin resistance has a shared pathogenic mechanism between depression and type 2 DM [17]. This could be relevant to the observation that depression often precedes diabetic symptoms in type 2 DM, and patients with higher levels of depression have been found to experience more complications with diabetes, reduced adherence to medical treatment and health behavior, such as maintaining a healthy diet, and depression seems to correlate with severe deteriorations and eventually death in patients with DM [18]. Naicker et al.’s longitudinal study examined mortality risk associated with type 2 DM and the presence of comorbid affective symptoms in a large Norwegian sample over 18 years [19]. Their study showed that mortality risk (1) increased in the presence of depression, anxiety, or both, (2) was higher with comorbid depression only, and (3) the highest risk of death occurred in men with type 2 DM and symptoms of depression only.

Depressive symptoms in people with diabetes appear to complicate medical intervention and correlate with therapeutic failure [20]. Given the relevance of comorbid psychological conditions in DM, it has been proposed that psychological interventions are important to maximize self-management and improve both glycemic and psychosocial outcomes in patients with DM [21]. Among various methods, mindfulness training has been used as an adjunct skillset to cognitive behavior therapy (CBT) or used as an alternative or complementary intervention [22]. Mindfulness originates from Buddhist teachings, and involves “moment-by-moment awareness that is cultivated by purposefully paying attention to things we ordinarily don't think of” ([23], p. 2). More specifically, mindfulness requires attentiveness to an immediate experience that is free from self-referential evaluation, value-based association or emotional reactivity [24, 25].

Since its inception in Western therapy [26], mindfulness training has been used effectively in numerous therapeutic programs to assist in attention and emotion regulation [27]. Mindfulness-based interventions (MBIs) are increasingly used to address a wide range of psychological and medical disorders [28] and have been shown to be efficacious in the clinical treatment of anxiety and mood dysfunctions [29,30,31]. There is also some evidence that MBIs may improve psychological and biological diabetes-care parameters. For instance, randomized controlled trials of MBIs have shown improvement in emotional well-being and decreased symptoms of depression and anxiety, as well as general psychological distress at 1-month follow-up [32], 1- and 2-month follow-up [33] and 3- to 9-month follow-up [34]. Other RCTs show that MBIs have resulted in reduced diabetes-related stress from pre- to post-treatment [35], and improvement in quality of life and use of coping strategies to improve diabetes-related self-care maintained at 3-month follow-up [22], although variations in the magnitude of their effects can occur across methods and patient groups (e.g., [36, 37]). In addition, these benefits were equally observed when patients attended individual sessions [38].

Mindfulness-integrated Cognitive Behavior Therapy (MiCBT) [39] is one of the evidence-based manualised MBIs, developed between 2001 and 2004 [40] to systematically integrate mindfulness meditation, in the Burmese Vipassana/Insight tradition, with core elements of cognitive-behavior therapy. MiCBT is usually delivered through a four-stage program across eight to 12 sessions, but it can be further adjusted according to the type and severity of symptoms. Participants learn first to internalize attention and develop experiential awareness and equanimity to improve attention and emotion regulation, and then use various types of exposure methods to externalize these skills in the contexts in which their impairment is triggered or maintained (see Method section for details).

The increasing use of MiCBT in clinical settings is partly due to its transdiagnostic applicability and to its emphasis on interoceptive desensitization and equanimity, both during mindfulness training and across all integrated behavioral tasks included in this approach [41]. The theoretical foundation of MiCBT is the co-emergence model of reinforcement [39, 42], which extends the traditional understanding of operant conditioning. This theoretical conceptualization is summarized in Appendix 1. There is mounting multidisciplinary evidence for the advantage of increasing interoceptive awareness and acceptance in mental health conditions [43]. These studies show clear indications of impaired interoceptive capacity in mental health disorders, which may explain why gains in interoceptive awareness and acceptance through mindfulness training tend to have transtherapeutic benefits [42, 44]. Accordingly, the transdiagnostic approach of MiCBT is of particular interest in conditions such as Diabetes because it enables clinicians to address active clinical symptoms and complex comorbidity across a wide range of conditions [45]. A quasi-experimental study also suggested that MiCBT is equally effective when implemented with individuals and groups (Unpublished), which provides flexibility in clinical settings where facilitating groups is impractical.

Several randomized controlled trials (RCTs) demonstrated the effectiveness of MiCBT across a range of contexts and conditions. For example, MiCBT was shown to be effective in treating anxiety and depression in pregnant women [46] and in women with multiple sclerosis [47] from pre- to post-treatment, reducing symptoms of obsessive–compulsive disorder with maintained gains at 1-month follow-up [48], reducing perceived pain and increasing pain self-efficacy in patients with breast cancer with gains maintained at 1-month follow-up [49], reducing anxiety, depression and fatigue while improving sleep quality and hope in patients with Multiple Sclerosis with gains maintained at 2-month follow-up [50, 51], changing gene expression in women with perinatal depression [52], and reducing sports-anxiety and pessimism, and increasing flow in competitive athletes from pre- to post-intervention [53]. Other studies demonstrated the efficacy of the interoceptive desensitization method used in MiCBT in both chronic pain with gains further increased at 2-month follow-up [54] and induced pain in student samples [55].

The effects of MiCBT on type 2 DM and co-morbid symptoms were initially explored in a quasi-experimental study in a New-Zealander population, where type 2 DM is also of epidemic proportion (Unpublished). Participants reported an overall improvement of self-efficacy in managing unhelpful behaviors and unpleasant thoughts, body sensations, emotions and relationship with others from pre- to post-treatment. They also reported an increased ability to manage clinical symptoms, greater self-compassion and improvement in diabetes self-care. We are aware of one study which investigated the effectiveness of MiCBT in type 2 DM in Iran [56]. The results showed that MiCBT led to significant decrease in emotional distress and improved treatment adherence and quality of life in people with DM.

The aim of the present study was to provide an evaluation of the effectiveness of MiCBT in an Iranian population with type 2 DM attending the Kurdistan Clinic of Diabetes, using an adaptive delivery of MiCBT that takes into account cultural and religious complexities in an Iranian population when implementing a methodology that partly originates from a Buddhist contemplative tradition. We provide a detailed clinical implementation of both stages of MiCBT implemented in this experiment beyond what other studies have presented thus far, including verbatim task instructions and clinical dialogues in Appendix 2. We were particularly interested in exploring the possible effects of MiCBT on comorbid depression, poor adherence to medical treatment and diabetes self-care, including blood glucose control.

Based on previous findings (e.g., [32, 37]), we predicted that depressive symptoms on the Beck Depression Inventory would decrease significantly more in the MiCBT group than in the treatment-as-usual (TAU) group. It was also hypothesized that participants in the MiCBT group would be more able to adhere to diabetes treatment and related self-care on the Adherence to Therapy Scale than those in the TAU group. We also expected that decreased depression, greater treatment adherence and related self-care following treatment would result in a greater blood sugar reduction in the MiCBT group than in the control group.

2 Method

2.1 Participants

All potential participants consisted of Kurdish-speaking patients with type 2 DM attending the Kurdistan Clinic of Diabetes for their medical treatment, most of whom had a long-term DM diagnosis. Ninety-five patients met the criterion for literacy: having at least the ability for reading and writing that equals elementary school education. From these, 36 met the remaining criteria and were invited to participate. The clinical criteria for inclusion were: (1) scoring at least 15 on the Beck Depression Inventory (BDI) as per Viinamäki et al.’s [57] recommendations, (2) having no other psychological intervention implemented concurrently, and (3) having no suicidal thoughts or intent, and no psychotic states or manic symptoms. Exclusion Criteria were (1) the necessity for, or existing prescription of, antidepressants or other psychiatric medication, (2) change of drugs for diabetes control, and (3) emerging suicidal ideation in the period of the intervention. A recurring reason for exclusion was logistical. Some participants could not attend due to living too far from the center. Another was that many were overly suspicious and unwilling to give informed consent. These reduced the potential sample down to 36. Consent issues, despite our strict application of standard Helsinki ethical guidelines, may be a reflection of population suspiciousness, sense of oppression, and inflated need for caution.

Of 36 possible participants, 25 (11 males and 14 females, mean age = 45.6) volunteered and provided consent to participate. Participants were randomly assigned to either the MiCBT group (n = 12) or the TAU (control) group (n = 13). All participants had been diagnosed with type 2 DM between 2 and 10 years prior to enrolling in the study. However, randomization did not specifically take illness duration into account. The study was explained to participants during their first contact with the experimenter. Participants then completed an initial demographics questionnaire, which included baseline data for levels of depression and medical treatment adherence. There were no significant between-group differences on demographic and baseline data (see Table 1).

Table 1 Demographic variables and statistical difference (Chi-Square) between variables

In both MiCBT and TAU groups, four participants failed to complete the forms and their data were excluded from the study. Their missing data were not obtainable. Intent-to-treat analysis (ITT) was not performed on the basis that ITT can only be performed where there is complete outcome data for all randomized participants [58] and the sample was too small to perform Maximum Likelihood Estimation or multiple imputation. Accordingly, only the data from eight participants in the MiCBT group and nine in the TAU group were retained. A comparison of baseline characteristics of participants who dropped out and those who did not is presented in Table 2. There were no significant differences in age and in all measures between included and excluded participants.

Table 2 Baseline characteristics of participants with complete (included) dataset and those with incomplete (excluded) dataset for each group and for the entire sample

2.2 Materials

For their home practice of mindfulness meditation, participants in the MiCBT group received either a 60-90 min individual session with audiotapes or a printed script format of the same instructions if they could not use the audio instructions due to not having means of playing audio instructions. Some participants had no smart phones or audio player, some had hearing problems. The original audio instructions [59] were first transcribed and translated in Farsi with the author’s permission.

Measures. The Beck Depression Inventory (BDI) [60] is a widely used self-report depression rating scale with 21 items requiring answers scored on a 4-point scale, ranging from 0 to 3. It is administered across a wide range of psychological disorders for adults and adolescents. The BDI was found to have good internal consistency and good convergent validity; Cronbach’s alpha between 0.73–0.90. We used the translated version (BDI-I) in Farsi [61], which shows good convergent validity and internal consistency; Cronbach alpha between 0.78–0.92. Despite the cross-cultural sample for this study, translated items of the BDI accurately captures the expression of depression in the Iranian population, in which it has been used extensively.

The Adherence to Therapy Scale [62, 63] is a 4-item self-report questionnaire used to measure the extent to which a person follows a therapy protocol, do an intended activity or prevent counterproductive behavior. In the current study, participants were asked to include DM-specific medical regimens, such as taking medication, exercising, following a diet, and keeping regular medical appointments. It is scored on a 6-point Likert scale, ranging from very poor (1) to excellent adherence (6). Its Farsi version [63] showed good convergent validity and acceptable internal consistency; Cronbach’s alpha = 0.71. The Glycosylated Hemoglobin Test (HbA1c) measures a person’s average levels of blood glucose over the past 2 to 3 months.

2.3 Procedure

After a first consideration of sufficient literacy and diagnosis (especially type of DM), the participants were invited by telephone for a pre-enrollment interview, during which the inclusion criteria were assessed, and the baseline measures implemented. Those who met inclusion criteria were invited to take part in the study and attend eight weekly sessions. These participants were randomly assigned to two groups: a MiCBT group and a TAU group through a simple randomized lottery. The intervention group received eight 60 to 90-min individual sessions of MiCBT, while the TAU group did not receive any psychological intervention during this period, but continued to receive their usual medical treatment, which included as frequent (medical) consultations as required by their medical practitioner, although these were shorter than MiCBT sessions. Equally, participants in the MiCBT group received medical consultations as required by their medical practitioner.

A postgraduate student of clinical psychology and practitioner of mindfulness meditation implemented MiCBT following Cayoun’s implementation manual [39], while supervised by an experienced clinical psychologist. The student had a personal regular practice of mindfulness meditation for about 12 months prior to the commencement of the study. The supervising clinical psychologist had a personal regular practice of mindfulness meditation for over five years, but neither was particularly experienced in MiCBT. Therapy was delivered in individual sessions, rather than in group, because it was thought to be a more suitable approach for an Iranian population. The first session included a DM-specific goal-setting activity as part of ‘therapy contracting’, and baseline data were collected. All participants were given their routine diabetic drugs and only the intervention group undertook Stage 1 (intrapersonal regulation) and Stage 2 (behavioral regulation) of the MiCBT program, summarized in Table 3.

Table 3 Summary of the first two (adapted) stages of MiCBT implemented in the current study

Participants in Stage 1 were taught to develop various mindfulness skillsets to improve attention and emotion regulation [27, 39], with an emphasis on body-scanning methods for the development of equanimity, as per the traditional teaching of Vipassana meditation in the Burmese tradition of Ledi Sayadaw, U Ba Khin, and Goenka [64]. Equanimity is an attitude toward personal experience which combines the inhibition of learned reactivity and the unconditional acceptance of the present experience [65]. Equanimity has been defined as “an even-minded mental state or dispositional tendency toward all experiences or objects, regardless of their affective valence (pleasant, unpleasant or neutral) or source” ([66], p. 357). Participants developed a degree of equanimity by surveying the body part by part, continuously and systematically, while learning to experience body sensations “just as body sensations” and preventing automatic reactions (see Appendix 2 for detailed implementation).

Once participants learned to apply and further develop equanimity with common stressors during the first three weeks of Stage 1 MiCBT, they undertook Stage 2 of MiCBT, as per the manualized instructions. However, more time was provided to participants who needed it and Stage 2 was delayed. The individual implementation facilitated these occasional adjustments. Stage 2 consists of two integrated exposure methods (imaginal and in vivo) that capitalize on the levels of equanimity developed during Stage 1 to decrease both experiential (interoceptive) and situational avoidance. Although the manualised structure of these MiCBT stages was purposefully unchanged to preserve and verify its transdiagnostic applicability, both interoceptive and exteroceptive exposure methods were set to reduce DM symptoms proliferation (see Appendix 2 for detailed implementation). It is recommended that the delivery schedule remains flexible enough to be delivered in an 8- to 12-week period, so that patients who struggle to acquire the expected skills have more time to do so before transitioning to subsequent behavioral and meditative stages [39].

Stage 3 provides training in interpersonal communication, and Stage 4 provides compassion training and explicit ethics (see [45], for detailed procedure of these stages). In this study, only stages 1 and 2 from the standard protocol were implemented within the eight sessions. This was primarily because these stages seemed to include the skillsets that were most congruent with the participants’ condition, and most culturally relatable to participants. The efficacy of the intervention with the truncation of stages was also a measurement of interest.

At the start and completion of the program, and at 6-week follow-up, all participants completed the BDI and Adherence to Therapy Scale and took the HbA1c test. Along with the other measures, the HbA1C test was taken at pre-treatment, post-treatment and follow-up. Each HbA1C test was sent to a medical laboratory for analysis. TAU involved the usual medical treatment, including medical visits, medication under the control of their physician and suggested diet, but excluded treatments of depression, such as antidepressants and psychological therapy. After the follow-up data and HbA1c test were collected on-site after meeting with the experimenter, participants in the TAU group received two sessions of counselling, relaxation training and mindfulness meditation.

2.4 Design

A 2 × 3 mixed factorial design was used, with Group (MiCBT, TAU) and Time (Pre-treatment, Post-Treatment, and 6-week follow-up) as independent variables. The dependent variables were the scores on each measure described above. Analyses of Variance (ANOVAs) were used to detect main effects and interactions between Group and Time, and pairwise comparisons and t-tests with Bonferroni adjustment were used for post-hoc analyses. Mauschly’s Test of Sphericity indicated that the assumption of sphericity was not violated for all ANOVAs. Raw data analysis found no outliers and Shapiro-Wilks and Kolmogorov–Smirnov tests showed a normal distribution. Incomplete data sets had to be excluded as the sample size was too small to use intent-to-treat analysis. Alpha levels were held at 0.05 and partial eta squared (ηp2) was used to estimate effect sizes. As per Cohen [67], norms for partial eta-squared were: small effect = 0.01; medium effect = 0.06; and large effect = 0.14.

3 Results

Baseline characteristics of participants with complete dataset (included in the study) and those with incomplete dataset (excluded from the study) were calculated for each group and for the entire sample using independent-samples t-tests. Table 4 shows means, standard deviations (SDs) and range for the three dependent measures.

Table 4 Mean, standard deviation (SD) and range (Min, Max) for all measures in both groups

4 Depression

A 2 × 3 ANOVA shows a significant Group by Time interaction, F(2,30) = 41.05, p < 0.001, ηp2 = 0.78, indicating a significantly greater decrease in depression in the MiCBT group than in the TAU group. A 2 × 2 ANOVA was used to assess the effect of MiCBT on Depression from pre- to post-treatment across groups. There was a significant Group by Time interaction, F(1,16) = 73.35, p < 0.001, ηp2 = 0.82, showing a larger decrease in depression from pre- to post-treatment in the MiCBT group, than in the TAU group. The pre-treatment to follow-up analysis also showed a significant interaction F(1,16) = 18.138, p < 0.001, ηp2 = 0.681, but no significant difference was found from post-treatment to follow-up F(1,16) = 0.084, p < 0.775, ηp2 = 0.617. Table 5 displays t-tests used for post-hoc analysis of group differences on the BDI, and within-subject differences and CIs for each group at each measurement time are shown in Table 6. Overall, the data show no group difference in depression at pre-treatment, and a large and statistically significant decrease in depression from pre- to post-treatment in the MiCBT group only. This difference was maintained at 6-week follow-up and the difference between groups remained. No differences were found in the TAU at any of the measurement times.

Table 5 Post-hoc analyses (t-tests) of between-group differences across times and measures
Table 6 Within-subject differences for each measure (pairwise comparisons)

4.1 Adherence

To examine the effect of MiCBT on Adherence, a 2 × 3 (Group by Time, respectively) ANOVA was used. Means and SDs are shown in Table 4. There was a significant interaction of Adherence by Time F(2,30) = 111.58; p < 0.001; ηp2 = 0.920, showing a significantly greater increase in levels of adherence to medical treatment in the MiCBT group than in the TAU group. A 2 × 2 ANOVA found a significant interaction of Time by Group, F(1,16) = 155.68, p < 0.001, ηp2 = 0.931, showing that adherence to medical treatment improved significantly more in the MiCBT group than in the TAU group from pre- to post-treatment. There was also a significant between-group difference in the same direction from pre-treatment to follow-up with large effect size F(1,16) = 7.733, p = 0.013, ηp2 = 0.66. Neither group showed a significant difference between post and follow-up measures F(1,16) = 0.084, p < 0.229, ηp2 = 0.84. Table 5 displays t-tests used for post-hoc analysis of group differences on adherence, and within-subject differences and CIs for each group at each measurement time are shown in Table 6. Overall, the data show no group difference in Adherence at pre-treatment, and a large and statistically significant increase in Adherence from pre- to post-treatment in the MiCBT group only. This difference was maintained at 6-week follow-up and the difference between groups remained. No differences were found in the TAU at any of the measurement times.

4.2 Blood sugar levels (HbA1c)

A 2 (Group) × 3 (Time) repeated measures ANOVA was used to examine the effect of MiCBT on HbA1C. Means and SDs for HbA1c are shown in Table 2. There was a significant Group by Time interaction F(2,30) = 2.213, p = 0.012; ηp2 = 0.186. As shown in Table 5, post-hoc analysis shows a significant between-group difference in blood sugar at 6-week follow-up. As shown by the within-subject analysis displayed in Table 6, pairwise comparisons indicate a significant and large decrease in blood sugar levels from pre- to post-treatment in the MiCBT group, but not in the TAU group. There was also a trend toward significance (p = 0.067) in blood sugar reduction with a large effect size from pre-treatment to follow-up, and no difference between post-treatment and follow-up.

5 Discussion

The aim of this pilot study was to evaluate the effects of adding Mindfulness-integrated Cognitive Behavior Therapy (MiCBT) to TAU compared to TAU alone in an Iranian sample of patients with type 2 DM. Our results support the results of previous studies of the efficacy of MBIs in improving the wellbeing of people with DM [10, 32, 33]. They also support our first hypothesis. Participants who undertook the MiCBT program experienced a significant reduction in depression from pre- to post-treatment, which was maintained at 6-week follow-up. No depression reduction was found in the TAU group and there was no between-group difference in depression at pre-treatment. Also, in agreement with our second hypothesis, there was a significant increase in medical treatment adherence in the MiCBT group from pre- to post-treatment, which was also maintained at 6-week follow-up. This did not occur in the TAU group. Our third prediction was also supported by the data, showing a significant blood sugar reduction from pre- to post-treatment in the MiCBT group, maintained at 6-week follow-up, and a significant between-group difference at 6-week follow-up. While these early results need to be replicated, they support the increasing observation that MBIs may be useful alternative ways of alleviating the burden of depression and reduced self-care behavior in people with DM.

None of the participants reported aversive effects from practicing mindfulness. This may be due to using a trauma-sensitive methodology which includes individual implementation, rather than group delivery. The small sample size may have also reduced the probability of undesired effects. It is not clear whether this is generalizable to large samples.

The comorbidity of depression with DM is well established, and more so in socially disadvantaged populations such as that of Iran in general. Renn et al.’s [68] cross-sectional study of depressive symptomatology in 424 patients with prediabetes or type 2 DM from disadvantaged populations in the US demonstrated that the majority (67.7%) of DM patients also showed depressive symptoms. This is close to the high prevalence of depression found in Iranian diabetic patients (71–78%), which seems proportionally related to the already high (37%) prevalence of depression in the general Iranian population [69]. Since depressive symptoms include dysregulated diet and low motivation for activity and exercise, it is possible that depression is driving the high rate of type 2 DM in Iran and other disadvantaged populations. If this were the case in the current study, it could be that the greater effect of MiCBT in the current study may have been on decreasing depressive symptoms, as measure by the BDI, which in turn may have had an effect on participants’ improved self-care, as measured here through treatment adherence and glycemic control. Accordingly, it is difficult to know whether this might impact the generalizability of the findings to other populations. To clarify this possible causal mechanism, future studies could examine the effects of MiCBT on participants with type 2 DM with and without depression and measure the effects that MiCBT (or other MBIs) may have on DM alone.

6 Limitations

A limitation of this study is the small sample size, and therefore lowered statistical power. With such small groups, caution must be applied when interpreting the results, as the findings might not be generalizable to the diabetic population at large. RCTs of MiCBT tend to show large effect sizes (d) ranging from 0.8 to 1.6. In this study, effects sizes were overall very large as well and easy to detect, but small effects in the TAU group may have been missed. Randomization could have also been improved by taking the duration of illness into account. Since all participants had been diagnosed between 2 and 10 years prior to enrolling in the study, and illness duration influences the effectiveness of diabetes education on lifestyle behavior modification and glycemic control [70], some variance may have been introduced. Ko et al. [70] recommend employing more intense, regular, and sustained reinforcement for people with longstanding type 2 diabetes (≥ 3 years). Accordingly, it is not clear whether illness-duration effects are more related to diabetes education than a comprehensive behavioral intervention such as MiCBT. Our results must therefore be interpreted with caution. Future studies with larger samples and controlling for illness duration are needed to assist in a more reliable examination of MiCBT effects in DM.

It was initially intended to measure participants’ adherence to meditation practice protocol. However, the participants’ home practice records were not consistently used or provided to the researchers and tracking daily practice could not be done effectively. Consequently, this measurement was not included in the analysis, which limits the ability to verify whether or not the amount of home practice of mindfulness impacted the outcomes. Future studies will need to adopt a more reliable protocol for measuring home practice. For example, where possible, a smart phone app could be used to guide and monitor practice (e.g., [71]).

Another limitation was the differential delivery of practice instructions in the MiCBT group. Whereas the standard means of learning to meditate in the MiCBT protocol is the intermittent use of audio instructions and silent practice, some participants in this study used a printed script format of the same instructions if they could not use audios (mostly due to logistics). Even though both audio and printed instructions contained the same information, the use of different learning modalities may have impacted practice accuracy or behavior, and potentially the outcome. Although participants in the MiCBT group improved significantly from pre to post treatment and maintained their gains at follow-up, there may have been within-group differences. All meditating participants learned each new method auditorily each week with the experimenter, but using home practice written instructions for the rest of the week would have required memory resources that were not necessary for those using audio instructions. Given the small sample per group, we were not able to do a meaningful statistical analysis for possible subgroup differences caused by these different learning modalities. Future studies would prevent potential confounds by providing home practice materials via the same delivery method. For participants who are unable to use a smart phone, when possible, researchers could provide a basic MP3 (audio) player or upload audio files on a website for participants to access online.

The altered implementation of the manualised MiCBT protocol from four to two stages was a potential limitation, especially in preventing relapse, which is the specific purpose of Stage 4 (the ‘empathic stage’). Our 6-week follow-up period was too short to elucidate this possibility. However, the simplified protocol in this study was also an opportunity to observe the beneficial effects of using only Stages 1 and 2 in type 2 DM. Developing attention- and emotion-regulation skills in Stage 1 and integrating these within exposure techniques in Stage 2 provided substantial benefits to participants. However, this small-scale study does not permit any reliable assertion that the effects of a simplified MiCBT program equates those of a full version. While the MiCBT approach is flexible enough to be adapted to client needs in clinical settings, time constraints in this study did not allow for any adaptation where it was needed. While this would have been a routine adjustment of the program in clinical settings, with a longer delivery for severe symptoms and personality disorders (Cayoun et al. [24]), the academic context of this study did not allow for adopting the developer’s recommendation of a flexible 8 to 12-session delivery. For instance, the daily practice of loving kindness and explicit ethics during Stage 4 teaches people to prevent harming themselves and others out of compassion. It teaches them to value themselves and care for themselves, which also means caring for their body and general well-being, including caring about what they eat. A self-implementation protocol of MiCBT suggests that the program can be further lengthened on a need basis. Hence, it is recommended that future studies allow more flexible time for implementation and approximate real-life delivery of the program (8–12 sessions), as it is possible that people with DM may make further progress, especially with decreasing blood sugar levels, if they are given more time. Nonetheless, the present study also shows that a simplified implementation remained efficacious in reducing the target symptoms in this sample.

Finally, mindfulness skills were not assessed. It is therefore difficult to know whether all or only some skillsets implemented in the first two stages of MiCBT were most beneficial. Including a mindfulness measure validated for the Iranian population would be advantageous in future studies. In addition, given the central role of equanimity in the cultivation and maintenance of mindfulness, future MBI studies with type 2 DM will benefit from using a measure of equanimity which includes items related to craving and avoidance, such as “I can pay attention to what is happening in my body without disliking or wanting more of the feeling or sensation” [64].

7 Future directions

The scope and sample size of this study did not allow for an examination of the possible contribution of gender and personality factors. Nyklíček et al. [36] found that women with diabetes and outpatients low in extraversion benefited most from Mindfulness-based Cognitive Therapy [31]. It is not clear whether these factors would also affect MiCBT outcomes, and future study may investigate this possibility. It may be that some MBIs are more suited to various patient groups with DM, such as individuals with high or low comorbidity, with or without personality disorders. In addition, assessing the possible inter-relatedness of psychological factors in DM would clarify the psychological profiles of DM and assist in selecting therapeutic goals more effectively.

MiCBT was shown to yield similar transdiagnostic benefits whether implemented in group or individual clinical settings. However, it is not clear whether such clinical settings would yield the same results for people with DM. Tovote et al. [37] used an individual delivery of MBCT and CBT, which produced significant reductions in depressive and anxiety symptoms, improved well-being, and diabetes-related distress, but no blood sugar reduction. It is not clear whether group dynamics, such as peer pressure, could have motivated participants to adhere to self-care and medical treatment, resulting in blood sugar reduction. It would be beneficial for future studies to investigate the possible differential effects of group versus individual delivery of MBIs in patients with DM.

Moreover, future studies may include mediation analysis, as it is not clear in this study whether improved emotion-regulation, as reflected through improved mood, mediated the effects on other variables (adherence and blood sugar); Alternatively, it is also possible that preventing avoidance through exposure (in Stage 2) may have improved adherence and assisted participants in feeling empowered and hopeful, thereby decreasing symptoms of depression. We also suggest that a longer follow-up period is necessary to show the fuller extent of the effect over time, since more time is necessary to address complex variables, such as personality factors. Future studies may show better outcome reliability by including a 6-month follow-up measure. Future studies may also include a way of rating the sessions for adherence and leader competence. Although the program in the current study was followed with integrity, such measure was not included. It would also be useful to compare the effects of the truncated version of MiCBT implemented in this study (stages 1 and 2) with the full version comprising the four stages. It is possible that a difference may emerge in the transdiagnostic efficacy. Since stages 1 and 2 focus on integrating mindfulness and CBT to assist in self-regulation and reducing avoidance, and 3 and 4 address impairments in interpersonal contexts and poor self-compassion, it may be that people with DM and comorbid interpersonal dysfunctions may benefit more from the full program.

8 Conclusion

In this study, adding MiCBT to TAU was markedly more effective than TAU alone in reducing depressive symptoms, increasing adherence to therapy and reducing blood sugar levels in people with type 2 DM. This is in support of the extant literature, which shows that MBIs are useful adjunctive treatments of DM, as they can help address common comorbid psychological symptoms. However, this study was limited by a small sample size and used a simplified implementation than the standard four-stage MiCBT protocol. To establish the effectiveness of MiCBT in this population, studies with larger sample sizes are needed to compare group with individual implementation, investigate gender and personality variables, and use longer follow-up periods to increase outcome reliability.